Allianz Asset Management GmbH Has $252,000 Stock Holdings in Sarepta Therapeutics, Inc. $SRPT

Allianz Asset Management GmbH trimmed its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 63.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,760 shares of the biotechnology company’s stock after selling 25,661 shares during the period. Allianz Asset Management GmbH’s holdings in Sarepta Therapeutics were worth $252,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SRPT. Janney Montgomery Scott LLC bought a new stake in shares of Sarepta Therapeutics in the 1st quarter valued at approximately $821,000. Cambridge Investment Research Advisors Inc. grew its stake in shares of Sarepta Therapeutics by 5.9% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 6,387 shares of the biotechnology company’s stock valued at $408,000 after purchasing an additional 358 shares during the period. New York State Teachers Retirement System grew its stake in shares of Sarepta Therapeutics by 3.3% in the 1st quarter. New York State Teachers Retirement System now owns 79,361 shares of the biotechnology company’s stock valued at $5,065,000 after purchasing an additional 2,512 shares during the period. Peregrine Capital Management LLC grew its stake in shares of Sarepta Therapeutics by 28.0% in the 1st quarter. Peregrine Capital Management LLC now owns 68,874 shares of the biotechnology company’s stock valued at $4,396,000 after purchasing an additional 15,070 shares during the period. Finally, GF Fund Management CO. LTD. grew its stake in shares of Sarepta Therapeutics by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 2,446 shares of the biotechnology company’s stock valued at $156,000 after purchasing an additional 440 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT opened at $24.22 on Wednesday. The company’s 50 day simple moving average is $20.03 and its 200 day simple moving average is $27.57. The stock has a market capitalization of $2.37 billion, a price-to-earnings ratio of -27.84 and a beta of 0.51. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.89 and a quick ratio of 1.81. Sarepta Therapeutics, Inc. has a 1 year low of $10.41 and a 1 year high of $138.81.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $1.13. The firm had revenue of $611.09 million for the quarter, compared to analysts’ expectations of $530.66 million. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The company’s revenue was up 68.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.07 earnings per share. As a group, research analysts predict that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on SRPT. Leerink Partnrs lowered Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 18th. Needham & Company LLC restated an “underperform” rating on shares of Sarepta Therapeutics in a research report on Monday, July 28th. Barclays raised Sarepta Therapeutics from an “underweight” rating to an “equal weight” rating and set a $22.00 price objective on the stock in a report on Tuesday, July 29th. Citigroup started coverage on Sarepta Therapeutics in a report on Tuesday, July 22nd. They set a “sell” rating on the stock. Finally, UBS Group reaffirmed a “neutral” rating on shares of Sarepta Therapeutics in a research note on Monday, July 21st. Eight analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and seven have given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $34.46.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.